31/03/2026
Happy World Theranostics Day!
Today we celebrate the science that's transforming cancer care, where diagnosis and therapy unite to fight disease with precision. See it! Treat it!
A huge congratulations to the team at CHRU de Nancy (Kunsch, Zaragori, Olivier, Claudin, Marie, Raymond, Heyer, Verger, Imbert & Boursier) on their landmark research published in the Journal of Nuclear Medicine, demonstrating the powerful prognostic value of serial total-body ¹⁷⁷Lu-PSMA SPECT imaging in metastatic castration-resistant prostate cancer.
https://jnm.snmjournals.org/content/66/11/1695
Their findings show that two key SPECT markers, the appearance of new bone lesions and final total lesion activity (TLA),can stratify patient survival. These markers outperform both PSA monitoring and pre-treatment PSMA PET/CT as survival predictors.
This was made possible by the VERITON-CT 360° CZT SPECT camera, which enables:
Total-body SPECT in just 18 minutes (vs. 36–90 min with conventional systems)
Serial scanning after every injection — tracking tumor evolution throughout the entire treatment course
Greater sensitivity for detecting new lesions and quantifying residual tumor burden
Theranostics isn't just about treating cancer, it's about understanding how each patient's tumor responds in real time and tailoring therapy accordingly. The VERITON-CT is making that vision a clinical reality.
Here's to the future of personalized, precision oncology!
Spectrum Dynamics Medical